Gilead: US Requests Documents About Angina Drug
14 Agosto 2009 - 6:11PM
Noticias Dow Jones
By Carla Mozee
Biotech firm Gilead Sciences Inc. (GILD) said Friday that it has
received a subpoena from the U.S. Department of Health and Human
Services requesting documents about the development, marketing and
sales of Ranexa.
Ranexa, which is used to treat chronic angina, was developed and
originally commercialized by CV Therapeutics, a company acquired by
Gilead in April.
-Carla Mozee; 415-439-6400; AskNewswires@dowjones.com